vs

Side-by-side financial comparison of Baird Medical Investment Holdings Ltd (BDMD) and cbdMD, Inc. (YCBD). Click either name above to swap in a different company.

Baird Medical Investment Holdings Ltd is the larger business by last-quarter revenue ($8.0M vs $5.0M, roughly 1.6× cbdMD, Inc.). cbdMD, Inc. runs the higher net margin — -5.6% vs -142.7%, a 137.1% gap on every dollar of revenue. cbdMD, Inc. produced more free cash flow last quarter ($-977.3K vs $-3.2M).

Baird Medical Investment Holdings Ltd is a healthcare-focused investment holding company mainly operating in the Chinese market. It invests in and manages businesses covering in vitro diagnostic devices, medical consumables, and community healthcare services, serving clinical institutions and individual consumers.

cbdMD, Inc. is a U.S.-based consumer wellness company that manufactures and distributes hemp-derived CBD products, including tinctures, topicals, gummies, pet care items, and bath products. All offerings undergo third-party quality testing, and are sold via e-commerce platforms, brick-and-mortar retail stores, and wellness partner channels primarily across the United States.

BDMD vs YCBD — Head-to-Head

Bigger by revenue
BDMD
BDMD
1.6× larger
BDMD
$8.0M
$5.0M
YCBD
Higher net margin
YCBD
YCBD
137.1% more per $
YCBD
-5.6%
-142.7%
BDMD
More free cash flow
YCBD
YCBD
$2.3M more FCF
YCBD
$-977.3K
$-3.2M
BDMD

Income Statement — Q2 FY2025 vs Q1 FY2026

Metric
BDMD
BDMD
YCBD
YCBD
Revenue
$8.0M
$5.0M
Net Profit
$-11.4M
$-283.1K
Gross Margin
82.1%
59.8%
Operating Margin
-131.3%
-5.7%
Net Margin
-142.7%
-5.6%
Revenue YoY
-1.9%
Net Profit YoY
-1975.7%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BDMD
BDMD
YCBD
YCBD
Q4 25
$5.0M
Q3 25
$4.7M
Q2 25
$8.0M
$4.6M
Q1 25
$4.7M
Q4 24
$5.1M
Q3 24
$4.6M
Q2 24
$5.2M
Q1 24
$4.4M
Net Profit
BDMD
BDMD
YCBD
YCBD
Q4 25
$-283.1K
Q3 25
$-680.0K
Q2 25
$-11.4M
$-895.3K
Q1 25
$-480.8K
Q4 24
$15.1K
Q3 24
$-152.8K
Q2 24
$459.7K
Q1 24
$-3.0M
Gross Margin
BDMD
BDMD
YCBD
YCBD
Q4 25
59.8%
Q3 25
58.8%
Q2 25
82.1%
61.5%
Q1 25
62.3%
Q4 24
66.5%
Q3 24
53.9%
Q2 24
65.8%
Q1 24
59.0%
Operating Margin
BDMD
BDMD
YCBD
YCBD
Q4 25
-5.7%
Q3 25
-14.5%
Q2 25
-131.3%
-19.6%
Q1 25
-10.2%
Q4 24
-1.7%
Q3 24
-6.9%
Q2 24
-7.4%
Q1 24
-35.4%
Net Margin
BDMD
BDMD
YCBD
YCBD
Q4 25
-5.6%
Q3 25
-14.4%
Q2 25
-142.7%
-19.4%
Q1 25
-10.1%
Q4 24
0.3%
Q3 24
-3.4%
Q2 24
8.9%
Q1 24
-68.8%
EPS (diluted)
BDMD
BDMD
YCBD
YCBD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$-0.15
Q1 24
$-1.35

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BDMD
BDMD
YCBD
YCBD
Cash + ST InvestmentsLiquidity on hand
$3.4M
Total DebtLower is stronger
$8.4M
Stockholders' EquityBook value
$35.6M
$9.0M
Total Assets
$77.0M
$11.8M
Debt / EquityLower = less leverage
0.24×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BDMD
BDMD
YCBD
YCBD
Q4 25
$3.4M
Q3 25
$2.3M
Q2 25
$1.1M
Q1 25
$1.8M
Q4 24
$2.0M
Q3 24
$2.5M
Q2 24
$2.4M
Q1 24
$2.1M
Total Debt
BDMD
BDMD
YCBD
YCBD
Q4 25
Q3 25
Q2 25
$8.4M
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
Stockholders' Equity
BDMD
BDMD
YCBD
YCBD
Q4 25
$9.0M
Q3 25
$7.2M
Q2 25
$35.6M
$6.1M
Q1 25
$665.8K
Q4 24
$1.8M
Q3 24
$2.0M
Q2 24
$3.0M
Q1 24
$3.1M
Total Assets
BDMD
BDMD
YCBD
YCBD
Q4 25
$11.8M
Q3 25
$10.4M
Q2 25
$77.0M
$9.9M
Q1 25
$10.9M
Q4 24
$11.5M
Q3 24
$10.6M
Q2 24
$13.8M
Q1 24
$14.6M
Debt / Equity
BDMD
BDMD
YCBD
YCBD
Q4 25
Q3 25
Q2 25
0.24×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BDMD
BDMD
YCBD
YCBD
Operating Cash FlowLast quarter
$-3.2M
$-812.5K
Free Cash FlowOCF − Capex
$-3.2M
$-977.3K
FCF MarginFCF / Revenue
-40.7%
-19.5%
Capex IntensityCapex / Revenue
0.6%
3.3%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-2.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BDMD
BDMD
YCBD
YCBD
Q4 25
$-812.5K
Q3 25
$-240.7K
Q2 25
$-3.2M
$-704.2K
Q1 25
$-189.5K
Q4 24
$-317.9K
Q3 24
$167.4K
Q2 24
$289.8K
Q1 24
$-704.1K
Free Cash Flow
BDMD
BDMD
YCBD
YCBD
Q4 25
$-977.3K
Q3 25
$-243.6K
Q2 25
$-3.2M
$-705.7K
Q1 25
$-205.0K
Q4 24
$-482.3K
Q3 24
$157.4K
Q2 24
Q1 24
$-708.7K
FCF Margin
BDMD
BDMD
YCBD
YCBD
Q4 25
-19.5%
Q3 25
-5.2%
Q2 25
-40.7%
-15.3%
Q1 25
-4.3%
Q4 24
-9.4%
Q3 24
3.5%
Q2 24
Q1 24
-16.2%
Capex Intensity
BDMD
BDMD
YCBD
YCBD
Q4 25
3.3%
Q3 25
0.1%
Q2 25
0.6%
0.0%
Q1 25
0.3%
Q4 24
3.2%
Q3 24
0.2%
Q2 24
0.0%
Q1 24
0.1%
Cash Conversion
BDMD
BDMD
YCBD
YCBD
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-21.06×
Q3 24
Q2 24
0.63×
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

BDMD
BDMD

Segment breakdown not available.

YCBD
YCBD

Sales Channel Directly To Consumer$3.6M72%
Sales Channel Through Intermediary$1.4M28%

Related Comparisons